desipramine Side Effects
Also known as: Norpramin
Analysis of 1,275 adverse event reports submitted to the FDA from 2004 to 2025.
Total Reports
1,275
Death-Related
217
17.0% of reports
Hospitalizations
341
26.7% of reports
Top Indication
Product Used For Unknown Indication
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 217 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| COMPLETED SUICIDE | 116 |
| TOXICITY TO VARIOUS AGENTS | 58 |
| DEATH | 36 |
| CARDIO-RESPIRATORY ARREST | 18 |
| DYSPNOEA | 17 |
| OVERDOSE | 17 |
| LOSS OF CONSCIOUSNESS | 16 |
| CONFUSIONAL STATE | 13 |
| CARDIAC ARREST | 12 |
| ANTIDEPRESSANT DRUG LEVEL ABOVE THERAPEUTIC | 11 |
| DRUG INTERACTION | 10 |
| SUSPECTED SUICIDE | 10 |
| RESPIRATORY ARREST | 8 |
| NEUROLEPTIC MALIGNANT SYNDROME | 7 |
| OFF LABEL USE | 7 |
| DRUG ABUSE | 6 |
| RENAL FAILURE | 6 |
| DRUG LEVEL INCREASED | 5 |
| VENTRICULAR FIBRILLATION | 5 |
| ACCIDENT | 4 |
Reactions in Hospitalization Reports
Top reactions in 341 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DRUG INEFFECTIVE | 29 |
| ACUTE KIDNEY INJURY | 28 |
| FATIGUE | 23 |
| HEADACHE | 23 |
| DYSPNOEA | 22 |
| DIZZINESS | 21 |
| FALL | 21 |
| NAUSEA | 21 |
| PAIN | 21 |
| COMPLETED SUICIDE | 20 |
| INTESTINAL OBSTRUCTION | 20 |
| OFF LABEL USE | 20 |
| URINARY RETENTION | 19 |
| WEIGHT DECREASED | 19 |
| ANXIETY | 18 |
| CHEST PAIN | 18 |
| LOSS OF CONSCIOUSNESS | 17 |
| ABDOMINAL PAIN | 16 |
| DEPRESSION | 16 |
| ILEUS | 16 |
Nearby — Related Medications
What the FAERS Data Reveals About desipramine Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 1,275 voluntary reports linked to desipramine and its brand equivalents (Norpramin), spanning 2004 through 2025. Of those, 217 (17.0%) listed death as an outcome and 341 (26.7%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 71% were female and 29% male; age distribution skews toward 45-64, with 385 reports in that bracket. The single most reported reaction is drug ineffective with 125 submissions, followed by fatigue and completed suicide.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.